Back
Science

Experimental Weight Loss Drug Retatrutide Available Online Despite Global Lack of Approval

Generated on: Last updated: 1 sources
View source

Unapproved Weight Loss Drug Retatrutide Circulates on Illicit Markets

Early clinical trial data indicates significant weight loss in participants, but health authorities warn of serious risks associated with unregulated products.

Despite not being approved for use in any country, an experimental peptide drug for weight loss, retatrutide, is being sold through illicit online markets. Health authorities are warning of the serious risks associated with these unregulated products.

Drug Profile and Development Status

Retatrutide is a peptide-based drug currently undergoing clinical trials for weight loss. It functions by targeting three hormone pathways in the body:

  • Glucagon-like peptide-1 (GLP-1)
  • Glucose-dependent insulinotropic polypeptide (GIP)
  • Glucagon

These pathways influence appetite, metabolism, and blood sugar levels.

The drug has not received regulatory approval for medical use anywhere in the world. All current efficacy and safety data are derived from controlled clinical trials, which are conducted under medical supervision with regulated dosing.

Reported Efficacy and Comparisons

Early results from a 2023 clinical trial indicated that participants receiving higher doses of retatrutide lost more than 20% of their body weight over a 48-week period.

In discussions of weight loss medications, retatrutide is sometimes compared to semaglutide, which is marketed under brand names including Ozempic and Wegovy. The early trial data suggests retatrutide may lead to greater weight loss.

Reported Risks and Side Effects

Data from clinical trials and anecdotal reports list several potential side effects and risks:

  • Gastrointestinal issues are commonly reported, including nausea, vomiting, diarrhea, and constipation.
  • At least one death has been reported in connection with the use of retatrutide. The individual developed severe diarrhea, and the case remains under investigation.
  • Some research suggests the drug may affect pathways in the brain related to reward and motivation. The potential impacts on mood, motivation, relationships, and sexual drive are not yet fully understood by researchers.
  • Rapid weight loss from such medications can also lead to a reduction in muscle mass if not accompanied by adequate protein intake and resistance training.

Illicit Market and Regulatory Warnings

Despite its unapproved status, retatrutide—sometimes referred to informally as "reta"—is available for purchase through illicit online markets.

Products sold through these unregulated channels pose specific dangers, as they may be contaminated, contain incorrect dosages, or contain no active ingredient at all.

Australia's Therapeutic Goods Administration (TGA) has issued a public warning about the dangers of importing and using unapproved peptide products. The online availability of retatrutide is reportedly linked to a trend among some gym-goers seeking rapid fat loss, a practice sometimes called "leanmaxxing."